Long-Term Assets: The sum of all assets classified as non-current.
SAB Biotherapeutics, Inc. (SABS) had Long-Term Assets of $71.76M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$4.26M |
|
-- |
|
-- |
|
$48.95M |
|
$-48.95M |
|
$62.23M |
|
$13.27M |
|
$13.27M |
|
$13.27M |
|
$13.27M |
|
$13.27M |
|
$13.27M |
|
$-48.95M |
|
$-45.96M |
|
19.31M |
|
61.34M |
|
$0.22 |
|
$-0.79 |
|
| Balance Sheet Financials | |
$101.05M |
|
$13.31M |
|
|
Long-Term Assets |
$71.76M |
$172.81M |
|
$10.68M |
|
$3.12M |
|
$10.63M |
|
$21.32M |
|
$151.49M |
|
$151.49M |
|
$151.49M |
|
47.61M |
|
| Cash Flow Statement Financials | |
$-44.78M |
|
$-121.71M |
|
$168.30M |
|
$8.90M |
|
$10.50M |
|
$1.60M |
|
$5.21M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.46 |
|
-- |
|
-- |
|
0.02 |
|
0.02 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-45.71M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
8.76% |
|
8.76% |
|
7.68% |
|
8.58% |
|
$3.18 |
|
$-0.75 |
|
$-0.73 |
|